|
CA2018248A1
(en)
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP1124568B1
(en)
|
1998-10-21 |
2007-08-22 |
Altor BioScience Corporation |
Polyspecific binding molecules and uses thereof
|
|
EP2322228B1
(en)
|
2000-06-05 |
2018-01-10 |
Altor BioScience Corporation |
T cell receptor fusion proteins and conjugates and methods of use thereof
|
|
EP1809669A2
(en)
|
2004-10-01 |
2007-07-25 |
Avidex Ltd |
T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
|
|
US7649083B2
(en)
|
2006-06-02 |
2010-01-19 |
Aveo Pharmaceuticals, Inc. |
Hepatocyte growth factor (HGF) binding antibody
|
|
CA2735193A1
(en)
|
2008-08-26 |
2010-03-11 |
Macrogenics, Inc. |
T-cell receptor antibodies and methods of use thereof
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
CN101928347B
(zh)
|
2010-05-05 |
2013-03-27 |
上海海抗中医药科技发展有限公司 |
抗癌胚抗原抗体及其应用
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
WO2013048243A1
(en)
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
US9580511B2
(en)
|
2013-03-11 |
2017-02-28 |
Genzyme Corporation |
Site-specific antibody-drug conjugation through glycoengineering
|
|
US20140308285A1
(en)
|
2013-03-15 |
2014-10-16 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
EP3027204B1
(en)
|
2013-07-29 |
2022-01-05 |
2seventy bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
CN106795220A
(zh)
|
2013-10-30 |
2017-05-31 |
建新公司 |
通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法
|
|
EP3220928B1
(en)
|
2014-11-20 |
2022-10-05 |
UMC Utrecht Holding B.V. |
A method of obtaining a preparation enrichmed in engineered t cells with exogenous immune receptors
|
|
GB201423361D0
(en)
|
2014-12-30 |
2015-02-11 |
Immatics Biotechnologies Gmbh |
Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
|
|
GB201504502D0
(en)
|
2015-03-17 |
2015-04-29 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
|
|
GB201505305D0
(en)
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
|
HRP20191800T1
(hr)
|
2015-05-13 |
2019-12-27 |
Ablynx N.V. |
Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
|
|
ES2984656T3
(es)
|
2015-05-13 |
2024-10-30 |
Ablynx Nv |
Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
|
|
GB201510771D0
(en)
|
2015-06-19 |
2015-08-05 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
|
|
GB201511191D0
(en)
|
2015-06-25 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
T-cell epitopes for the immunotherapy of myeloma
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
GB201511792D0
(en)
|
2015-07-06 |
2015-08-19 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
|
|
GB201512369D0
(en)
|
2015-07-15 |
2015-08-19 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
US10159726B2
(en)
|
2015-08-28 |
2018-12-25 |
Immatics Biotechnologies Gmbh |
Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
|
|
GB201517538D0
(en)
|
2015-10-05 |
2015-11-18 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
|
|
WO2017060201A1
(en)
|
2015-10-09 |
2017-04-13 |
Immatics Biotechnologies Gmbh |
Anti-wt1/hla-specific antibodies
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
GB201604468D0
(en)
|
2016-03-16 |
2016-04-27 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520595D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520539D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520589D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520564D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520559D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201521746D0
(en)
|
2015-12-10 |
2016-01-27 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
|
|
GB201521894D0
(en)
|
2015-12-11 |
2016-01-27 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against various cancers
|
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
|
GB201603568D0
(en)
|
2016-03-01 |
2016-04-13 |
Immatics Biotechnologies Gmbh |
Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
|
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
|
GB201604494D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
|
|
GB201604492D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
WO2017167350A1
(en)
|
2016-03-30 |
2017-10-05 |
Horst Lindhofer |
Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
|
|
DE102016115246C5
(de)
|
2016-08-17 |
2018-12-20 |
Immatics Biotechnologies Gmbh |
Neue t-zellrezeptoren und deren verwendung in immuntherapie
|
|
ZA201900664B
(en)
|
2016-08-17 |
2021-09-29 |
Paul Ehrlich Strasse 15 Tuebingen 72076 Germany |
T cell receptors and immune therapy using the same
|
|
EP3300863B1
(en)
|
2016-09-28 |
2020-06-17 |
Braun GmbH |
Electric shaver
|
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
DE102016123859B3
(de)
|
2016-12-08 |
2018-03-01 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
DE102016123847B3
(de)
|
2016-12-08 |
2018-04-05 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
DE102017106305A1
(de)
|
2017-03-23 |
2018-09-27 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
|
|
TW201841934A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於治療癌症免疫治療的新穎肽及其肽組合物
|
|
TW201841937A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於白血病和其他癌症免疫治療的新穎肽和肽組合物
|
|
DE102017114737A1
(de)
|
2017-06-30 |
2019-01-03 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
WO2019033050A1
(en)
|
2017-08-11 |
2019-02-14 |
City Of Hope |
BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
|
|
AU2018314236B2
(en)
|
2017-08-11 |
2025-02-06 |
Apterna Limited |
RNA aptamers against transferrin receptor (TfR)
|
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
|
JPWO2019151392A1
(ja)
|
2018-01-31 |
2021-02-04 |
国立大学法人東北大学 |
抗原特異的mhc発現調節法
|
|
KR20200119840A
(ko)
|
2018-02-09 |
2020-10-20 |
이매틱스 유에스 인코포레이티드 |
T 세포의 제조 방법
|
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
CN112469440B
(zh)
|
2018-06-18 |
2024-09-06 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
|
US12162947B2
(en)
|
2018-09-04 |
2024-12-10 |
Nanjing Umab-Biopharma Co., Ltd. |
Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection
|
|
EP3890773A4
(en)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
MODULATION OF DENDRITIC CELL LINES
|
|
JP7700039B2
(ja)
|
2019-01-04 |
2025-06-30 |
マレンゴ・セラピューティクス,インコーポレーテッド |
抗tcr抗体分子およびその使用
|
|
WO2020150364A1
(en)
|
2019-01-15 |
2020-07-23 |
Altor Bioscience, Llc |
Human immunodeficiency virus-specific t cell receptors
|
|
LT4279082T
(lt)
|
2019-01-17 |
2026-05-11 |
Immunocore Limited |
Farmacinės kompozicijos
|
|
GB201901306D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Multi-domain binding molecules
|
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
|
BR112021015009A2
(pt)
|
2019-02-15 |
2021-10-05 |
Allakos Inc. |
Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
|
|
US12473346B2
(en)
|
2019-03-18 |
2025-11-18 |
Ludwig Institute For Cancer Research Ltd |
A2/NY-ESO-1 specific t cell receptors and uses thereof
|
|
GB201904328D0
(en)
|
2019-03-28 |
2019-05-15 |
Immunocore Ltd |
Specific binding molecules
|
|
AU2020279224B2
(en)
*
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
KR20220012313A
(ko)
|
2019-05-23 |
2022-02-03 |
벨로스바이오 인코포레이티드 |
항-ror1/항-cd3 이중특이적 결합 분자
|
|
WO2020238926A1
(en)
|
2019-05-28 |
2020-12-03 |
Single Cell Technology, Inc. |
Anti-b7-h3 antibodies
|
|
TWI844684B
(zh)
|
2019-06-04 |
2024-06-11 |
大陸商普米斯生物技術(珠海)有限公司 |
一種抗ceacam5的單殖株抗體及其製備方法和用途
|
|
EP3980129A1
(en)
|
2019-06-07 |
2022-04-13 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
CA3141914A1
(en)
|
2019-06-07 |
2020-12-10 |
Adimab, Llc |
Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
|
|
MX2021015533A
(es)
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
MX2022001403A
(es)
|
2019-08-02 |
2022-03-25 |
Allakos Inc |
Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
|
|
EP3907240A4
(en)
|
2019-08-02 |
2023-02-22 |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
ANTI-TNFR2 ANTIBODIES AND USE THEREOF
|
|
US20210032370A1
(en)
*
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
|
DE102019121007A1
(de)
*
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
CN112390892B
(zh)
|
2019-08-14 |
2024-01-12 |
博源润生医药(杭州)有限公司 |
一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
|
|
CN111454357B
(zh)
|
2019-08-14 |
2022-03-15 |
康诺亚生物医药科技(成都)有限公司 |
一种含有抗体的肿瘤治疗剂的开发和应用
|
|
JP2022544543A
(ja)
|
2019-08-15 |
2022-10-19 |
シルバーバック セラピューティックス インコーポレイテッド |
ベンザゼピンコンジュゲートの製剤およびその使用
|
|
KR20220050971A
(ko)
|
2019-08-27 |
2022-04-25 |
엘피사이언스 (쑤저우) 바이오파마, 엘티디. |
신규 항-cd39 항체
|
|
GB201912681D0
(en)
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
|
KR20220088428A
(ko)
|
2019-09-26 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
|
|
US10975169B1
(en)
|
2019-09-27 |
2021-04-13 |
Memorial Sloan Kettering Cancer Center |
Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
|
|
AU2020358898B2
(en)
|
2019-10-01 |
2025-10-16 |
Epsilogen Ltd |
Hybrid antibody
|
|
CN114828861A
(zh)
|
2019-10-10 |
2022-07-29 |
亚利桑那州立大学董事会 |
表达多特异性免疫细胞接合器的溶瘤病毒
|
|
BR112022007128A2
(pt)
|
2019-10-15 |
2022-07-05 |
Dragonfly Therapeutics Inc |
Ligação de proteínas nkg2d, cd16 e flt3
|
|
CN115348972A
(zh)
|
2019-10-15 |
2022-11-15 |
蜻蜓疗法股份有限公司 |
靶向flt3的抗体及其用途
|
|
CN114729305A
(zh)
*
|
2019-10-17 |
2022-07-08 |
苏州丹罗医药有限公司 |
用于免疫治疗的嵌合抗原受体、制备方法及其应用
|
|
JP7450710B2
(ja)
|
2019-10-21 |
2024-03-15 |
上▲海▼宏成▲薬▼▲業▼有限公司 |
抗pd-l1抗体及びその製薬用途
|
|
GB201915282D0
(en)
|
2019-10-22 |
2019-12-04 |
Immunocore Ltd |
Specific binding molecules
|
|
EP4048701A4
(en)
|
2019-10-23 |
2024-05-29 |
Lyvgen Biopharma Holdings Limited |
Anti-cd40 binding molecules and bi-specific antibodies comprising such
|
|
EP4051712A4
(en)
|
2019-11-01 |
2023-11-29 |
Merck Sharp & Dohme LLC |
Dosing regimen of anti-cd27 antibodies for treatment of cancer
|
|
CN115038718B
(zh)
|
2019-11-08 |
2024-07-02 |
山东先声生物制药有限公司 |
抗人程序性死亡配体-1(pd-l1)的抗体及其用途
|
|
US20220380720A1
(en)
|
2019-11-12 |
2022-12-01 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
|
KR20220115572A
(ko)
|
2019-11-18 |
2022-08-17 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
항-b7-h3 단클론성 항체 및 이의 사용 방법
|
|
IL293108A
(en)
|
2019-11-19 |
2022-07-01 |
Univ Pennsylvania |
Monoclonal antibodies against alpha-synuclein, and methods of using them
|
|
NL2024375B1
(en)
|
2019-12-04 |
2021-08-31 |
Apo T B V |
Methods and means for attracting immune effector cells to tumor cells.
|
|
MX2022006676A
(es)
|
2019-12-04 |
2022-07-05 |
Ac Immune Sa |
Nuevas moleculas para terapia y diagnostico.
|
|
WO2021113831A1
(en)
|
2019-12-05 |
2021-06-10 |
Compugen Ltd. |
Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
|
|
EP4069735A1
(en)
|
2019-12-06 |
2022-10-12 |
OncoOne Research & Development GmbH |
Anti-oxmif/anti-cd3 bispecific antibody constructs
|
|
CN115916818A
(zh)
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
CN115515678A
(zh)
|
2019-12-23 |
2022-12-23 |
基因泰克公司 |
载脂蛋白l1特异性抗体及其使用方法
|
|
US20230054266A1
(en)
|
2019-12-30 |
2023-02-23 |
Edigene Biotechnology Inc. |
Method for purifying ucart cell and use thereof
|
|
EP4086340A1
(en)
|
2019-12-30 |
2022-11-09 |
Edigene Biotechnology Inc. |
Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
|
|
CN113088495B
(zh)
|
2020-01-09 |
2024-08-16 |
苏州方德门达新药开发有限公司 |
工程改造的t细胞、其制备及应用
|
|
US20230338421A1
(en)
|
2020-01-10 |
2023-10-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for autoimmunity regulation
|
|
CN119930824A
(zh)
|
2020-01-13 |
2025-05-06 |
真和制药有限公司 |
抗Gal3抗体和使用方法
|
|
CN115768483A
(zh)
|
2020-01-13 |
2023-03-07 |
西纳福克斯股份有限公司 |
抗体与免疫细胞衔接器的缀合物
|
|
CN113214395A
(zh)
|
2020-01-21 |
2021-08-06 |
迈威(上海)生物科技股份有限公司 |
抗st2抗体及其应用
|
|
US12692311B2
(en)
|
2020-01-29 |
2026-07-28 |
William Robert Arathoon Living Trust Dated August 29, 2016 |
Anti-MDR1 antibodies and uses thereof
|
|
US11976133B2
(en)
|
2020-01-31 |
2024-05-07 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
BR102020002165A2
(pt)
|
2020-01-31 |
2021-11-30 |
Fundação Oswaldo Cruz |
Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas.
|
|
EP4103618A4
(en)
|
2020-02-12 |
2024-05-01 |
The Scripps Research Institute |
LONG-ACTING GM-CSF AND METHODS OF USE
|
|
BR112022015982A2
(pt)
|
2020-02-12 |
2022-10-11 |
Abbvie Inc |
Moléculas de ligação bispecíficas
|
|
AU2021227406A1
(en)
|
2020-02-24 |
2022-09-29 |
Oblique Therapeutics Ab |
Kras epitopes and antibodies
|
|
CN115279412A
(zh)
|
2020-02-27 |
2022-11-01 |
凡恩世制药公司 |
偶联脂肪酸分子的抗体及其用途
|
|
JP2023516008A
(ja)
|
2020-02-27 |
2023-04-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
US20240067738A1
(en)
|
2020-03-18 |
2024-02-29 |
Elanco Us Inc. |
Anti-il4 receptor antibodies for veterinary use
|
|
MX2022011958A
(es)
|
2020-03-27 |
2023-01-11 |
Angiex Inc |
Conjugados de anticuerpo degradador y métodos de uso de los mismos.
|
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
|
EP4132578A1
(en)
|
2020-04-06 |
2023-02-15 |
Universität Zürich |
Artc1 ligands for cancer treatment
|
|
GB202005216D0
(en)
|
2020-04-08 |
2020-05-20 |
Autolus Ltd |
Cell
|
|
JP2023521228A
(ja)
|
2020-04-14 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
癌の併用療法
|
|
AU2021256925A1
(en)
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
|
WO2021209356A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CN116096413A
(zh)
|
2020-04-22 |
2023-05-09 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
|
JP2023524102A
(ja)
|
2020-04-30 |
2023-06-08 |
ザ チルドレンズ メディカル センター コーポレーション |
Abcb5に特異的な抗体およびその使用
|
|
WO2021222783A1
(en)
|
2020-05-01 |
2021-11-04 |
Angiex, Inc. |
Anti-tm4sf1 antibody drug conjugates and methods of using same
|
|
CN116096754A
(zh)
|
2020-05-04 |
2023-05-09 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
GB202006629D0
(en)
|
2020-05-05 |
2020-06-17 |
Immunocore Ltd |
Specific binding molecules
|
|
CN121914272A
(zh)
|
2020-05-12 |
2026-04-24 |
正大天晴药业集团股份有限公司 |
St2抗原结合蛋白
|
|
MX2022014786A
(es)
|
2020-05-26 |
2023-01-16 |
Truebinding Inc |
Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
|
|
CA3181776A1
(en)
|
2020-05-26 |
2021-12-02 |
Boehringer Ingelheim International Gmbh |
Anti-pd-1 antibodies
|
|
WO2021237717A1
(zh)
|
2020-05-29 |
2021-12-02 |
武汉友芝友生物制药有限公司 |
抗cldn18.2和cd3的双特异性抗体
|
|
CN113754766A
(zh)
|
2020-06-02 |
2021-12-07 |
明慧医药(上海)有限公司 |
抗b7-h3抗体及其制备和应用
|
|
KR20230021018A
(ko)
|
2020-06-05 |
2023-02-13 |
재단법인 생물기술개발중심 |
항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
IL299339A
(en)
|
2020-06-23 |
2023-02-01 |
Antengene Biologics Ltd |
Antibodies and methods for treating claudin-related diseases
|
|
EP3932944A1
(en)
|
2020-06-29 |
2022-01-05 |
GlaxoSmithKline Biologicals S.A. |
Hsv ge antibodies
|
|
EP4172195A1
(en)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Hsv gegi heterodimer antibodies
|
|
CN111662384B
(zh)
|
2020-06-30 |
2021-04-09 |
广州百暨基因科技有限公司 |
抗b7h3抗体及其应用
|
|
BR112022026533A2
(pt)
|
2020-07-02 |
2023-01-17 |
Beijing Tuo Jie Biopharmaceutical Co Ltd |
Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
|
|
WO2022005678A1
(en)
|
2020-07-02 |
2022-01-06 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Dual chimeric antigen receptor t cells targeting ccd99- and clec12a-expressing cancers
|
|
GB202010329D0
(en)
|
2020-07-06 |
2020-08-19 |
Immunocore Ltd |
Specific binding molecules
|
|
EP4188449A4
(en)
|
2020-07-31 |
2025-12-17 |
Angiex Inc |
ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH
|
|
JP2023536935A
(ja)
|
2020-08-07 |
2023-08-30 |
ノヴェルジェン カンパニー リミテッド |
コロナウイルスに対する抗ウイルス用組成物
|
|
KR102799318B1
(ko)
|
2020-08-11 |
2025-04-23 |
주식회사 카나프테라퓨틱스 |
Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
|
|
US20220119824A1
(en)
|
2020-08-12 |
2022-04-21 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
EP3957308A1
(en)
|
2020-08-21 |
2022-02-23 |
Palobiofarma, S.L. |
(1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
|
|
US12037409B2
(en)
|
2020-08-21 |
2024-07-16 |
Shanghai GenBase Biotechnology Co., Ltd. |
Antibody specifically bound to glycosylated CEACAM5
|
|
JP7748105B2
(ja)
|
2020-08-25 |
2025-10-02 |
学校法人 久留米大学 |
ウイルス感染の判定方法
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2022046941A1
(en)
|
2020-08-26 |
2022-03-03 |
Angiex, Inc. |
Antimitotic tetrapeptide-antibody conjugates and methods of using same
|
|
WO2022045247A1
(ja)
|
2020-08-27 |
2022-03-03 |
学校法人順天堂 |
抗切断型変異calr-cd3二重特異性抗体及び医薬組成物
|
|
JP2023540373A
(ja)
|
2020-09-08 |
2023-09-22 |
ノヴェルジェン カンパニー リミテッド |
インフルエンザaウイルスに対する抗ウイルス用組成物
|
|
US20230355764A1
(en)
|
2020-09-13 |
2023-11-09 |
Shandong Boan Biotechnology Co., Ltd. |
Downregulation of membrane-bound proteins by receptor tac technology
|
|
WO2022061032A1
(en)
|
2020-09-17 |
2022-03-24 |
Allakos Inc. |
Methods and compositions for treating viral infection
|
|
WO2022057941A1
(zh)
|
2020-09-21 |
2022-03-24 |
克莱格医学有限公司 |
表达il-7r结合蛋白的免疫效应细胞
|
|
WO2022063272A1
(en)
|
2020-09-28 |
2022-03-31 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel anti-claudin18 antibodies
|
|
CA3196055A1
(en)
|
2020-09-28 |
2022-03-31 |
Navrogen, Inc. |
Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer
|
|
CN116419971A
(zh)
|
2020-09-30 |
2023-07-11 |
南京金斯瑞生物科技有限公司 |
抗SARS-CoV-2刺突蛋白膜外区的单克隆抗体及其应用
|
|
WO2022072538A1
(en)
|
2020-09-30 |
2022-04-07 |
Biotheryx, Inc. |
Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022082068A1
(en)
|
2020-10-18 |
2022-04-21 |
Ardeagen Corporation |
Anti-msln binding agents, conjugates thereof and methods of using the same
|
|
AU2021365008A1
(en)
|
2020-10-22 |
2023-06-08 |
Allakos Inc. |
Anti-siglec-8 antibody formulations
|
|
WO2022094174A1
(en)
|
2020-10-30 |
2022-05-05 |
Children's Hospital Medical Center |
Compositions and methods for the treatment of esophageal conditions
|
|
US12116411B2
(en)
|
2020-11-03 |
2024-10-15 |
Abzyme Therapeutics Llc |
Antibodies binding to human CD3 at acidic pH
|
|
US20240010747A1
(en)
|
2020-11-13 |
2024-01-11 |
Kenjockety Biotechnology, Inc. |
Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
|
|
EP4251650A4
(en)
|
2020-11-27 |
2024-10-23 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel conjugate molecules targeting cd39 and tgfbeta
|
|
CN116964090A
(zh)
|
2020-12-14 |
2023-10-27 |
武田药品工业有限公司 |
条件性双特异性结合蛋白
|
|
CN114634566B
(zh)
|
2020-12-16 |
2023-09-19 |
广州百暨基因科技有限公司 |
一种抗Claudin18_2的抗原结合片段、抗体及其应用
|
|
US20240317871A1
(en)
|
2020-12-30 |
2024-09-26 |
Immunomic Therapeutics, Inc. |
Anti-HVEM Antibodies
|
|
WO2022148736A1
(en)
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
|
EP4271387A4
(en)
|
2021-01-07 |
2026-01-28 |
Immunext Inc |
NEW STEROID PAYLOAD, STEROID BINDERS, CONTAINERS AND ASSOCIATED USES
|
|
EP4032910A1
(en)
|
2021-01-22 |
2022-07-27 |
ETH Zurich |
Bispecific binding agent that binds to cd3 and a fluorophore
|
|
JP2024506022A
(ja)
|
2021-02-08 |
2024-02-08 |
シンアフィックス ビー.ブイ. |
多機能性抗体
|
|
IL305175A
(en)
|
2021-02-19 |
2023-10-01 |
Angeles Therapeutics Inc |
Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
|